Decision-Making Factors for Systemic Therapies in Atopic Dermatitis: A Clinical Review - PubMed
6 hours ago
- #JAK-inhibitors
- #biologics
- #atopic-dermatitis
- Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease affecting quality of life.
- Treatment has evolved from broad immunosuppressants to targeted biologics and small-molecule therapies.
- FDA-approved biologics include dupilumab, tralokinumab, lebrikizumab, and nemolizumab, showing efficacy and long-term safety.
- Oral JAK inhibitors (JAKis) like abrocitinib, upadacitinib, and baricitinib offer rapid disease control but have black-box warnings.
- Comparative trials show JAKis provide faster itch relief, while biologics offer durable disease control and safety advantages.
- Individualized therapy selection is crucial, considering factors like age, pregnancy, comorbidities, and adverse effects.
- Patient preferences (dosing frequency, administration route, self-injection willingness) and affordability influence treatment decisions.
- Future research focuses on comparative studies, biomarker development, and equitable access to advanced therapies.
- This review synthesizes evidence on biologics and JAKis in AD to guide dermatologists in clinical decision-making.